The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial
Why the study?
Does adding ezetimibe to statin therapy improve cardiovascular outcomes in post-ACS patients with prior CABG?
Population
18,134 post-ACS patients with mean LDL-C of 93.8 mg/dL at presentation, including a subgroup of 1,684 with…
Comparison
Simvastatin/ezetimibe vs Simvastatin/placebo
Design
RCT, Randomized
Follow-up
median 6 years
Authors
Discussion
Loading...
Member takes
Implication
Enhanced absolute benefit supports ezetimibe addition to statin in post-ACS with prior CABG; extends intensive lipid-lowering evidence to this high-risk subgroup.
Structured PICO
Does adding ezetimibe to statin therapy improve cardiovascular outcomes in post-ACS patients with prior CABG?
P
Population
18,134 post-ACS patients with mean LDL-C of 93.8 mg/dL at presentation, including a subgroup of 1,684 (9.3%) with prior CABG (median age 69 years, 82% male).
I
Intervention
Simvastatin/ezetimibe
C
Comparator
Simvastatin/placebo
O
Outcome
Composite of cardiovascular death, major coronary event or stroke at median 6 years follow-upcomposite
Adding ezetimibe to statin therapy provides an enhanced absolute clinical benefit in post-ACS patients with prior CABG, supporting intensive lipid lowering in this high-risk group.
Cite This Study
Eisen et al. (2016) studied this question.